{"doc_id": "33197395", "type of study": "Therapy", "title": "", "abstract": "Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.\nIntravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency.\nWe aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure.\nAFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore.\nEligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin <100 \u03bcg/L, or 100-299 \u03bcg/L with transferrin saturation <20%), and had a left ventricular ejection fraction of less than 50%.\nBefore hospital discharge, participants were randomly assigned (1:1) to receive intravenous ferric carboxymaltose or placebo for up to 24 weeks, dosed according to the extent of iron deficiency.\nTo maintain masking of patients and study personnel, treatments were administered in black syringes by personnel not involved in any study assessments.\nThe primary outcome was a composite of total hospitalisations for heart failure and cardiovascular death up to 52 weeks after randomisation, analysed in all patients who received at least one dose of study treatment and had at least one post-randomisation data point.\nSecondary outcomes were the composite of total cardiovascular hospitalisations and cardiovascular death; cardiovascular death; total heart failure hospitalisations; time to first heart failure hospitalisation or cardiovascular death; and days lost due to heart failure hospitalisations or cardiovascular death, all evaluated up to 52 weeks after randomisation.\nSafety was assessed in all patients for whom study treatment was started.\nA pre-COVID-19 sensitivity analysis on the primary and secondary outcomes was prespecified.\nThis study is registered with ClinicalTrials.gov, NCT02937454, and has now been completed.\nBetween March 21, 2017, and July 30, 2019, 1525 patients were screened, of whom 1132 patients were randomly assigned to study groups.\nStudy treatment was started in 1110 patients, and 1108 (558 in the carboxymaltose group and 550 in the placebo group) had at least one post-randomisation value.\n293 primary events (57\u00b72 per 100 patient-years) occurred in the ferric carboxymaltose group and 372 (72\u00b75 per 100 patient-years) occurred in the placebo group (rate ratio [RR] 0\u00b779, 95% CI 0\u00b762-1\u00b701, p=0\u00b7059).\n370 total cardiovascular hospitalisations and cardiovascular deaths occurred in the ferric carboxymaltose group and 451 occurred in the placebo group (RR 0\u00b780, 95% CI 0\u00b764-1\u00b700, p=0\u00b7050).\nThere was no difference in cardiovascular death between the two groups (77 [14%] of 558 in the ferric carboxymaltose group vs 78 [14%] in the placebo group; hazard ratio [HR] 0\u00b796, 95% CI 0\u00b770-1\u00b732, p=0\u00b781).\n217 total heart failure hospitalisations occurred in the ferric carboxymaltose group and 294 occurred in the placebo group (RR 0\u00b774; 95% CI 0\u00b758-0\u00b794, p=0\u00b7013).\nThe composite of first heart failure hospitalisation or cardiovascular death occurred in 181 (32%) patients in the ferric carboxymaltose group and 209 (38%) in the placebo group (HR 0\u00b780, 95% CI 0\u00b766-0\u00b798, p=0\u00b7030).\nFewer days were lost due to heart failure hospitalisations and cardiovascular death for patients assigned to ferric carboxymaltose compared with placebo (369 days per 100 patient-years vs 548 days per 100 patient-years; RR 0\u00b767, 95% CI 0\u00b747-0\u00b797, p=0\u00b7035).\nSerious adverse events occurred in 250 (45%) of 559 patients in the ferric carboxymaltose group and 282 (51%) of 551 patients in the placebo group.\nIn patients with iron deficiency, a left ventricular ejection fraction of less than 50%, and who were stabilised after an episode of acute heart failure, treatment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations, with no apparent effect on the risk of cardiovascular death.\nVifor Pharma.\nCopyright \u00a9 2020 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "iron deficiency at discharge", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 54}, {"term": "acute heart failure", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 80}, {"term": "heart failure", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 127}, {"term": "iron deficiency", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 147}, {"term": "acute", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 152}, {"term": "hospitalised", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 65}, {"term": "acute heart failure", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 89}, {"term": "concomitant iron deficiency", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 122}, {"term": "iron deficiency", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 32}, {"term": "left ventricular ejection fraction of less than 50 %", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 89}, {"term": "acute heart failure", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 155}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Ferric carboxymaltose for iron deficiency at discharge after acute heart failure : a multicentre , double-blind , randomised , controlled trial .", "Evidence Elements": {"Participant": [{"term": "iron deficiency at discharge", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 54}, {"term": "acute heart failure", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 80}], "Intervention": [{"term": "Ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 21}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency .", "Evidence Elements": {"Participant": [{"term": "heart failure", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 127}, {"term": "iron deficiency", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 147}], "Intervention": [], "Outcome": [{"term": "symptoms", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 68}, {"term": "quality of life", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 88}], "Observation": [{"term": "improve", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 59}], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We aimed to evaluate the effect of ferric carboxymaltose , compared with placebo , on outcomes in patients who were stabilised after an episode of acute heart failure .", "Evidence Elements": {"Participant": [{"term": "acute", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 152}], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 56}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 80}], "Outcome": [{"term": "outcomes", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 94}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "AFFIRM-AHF was a multicentre , double-blind , randomised trial done at 121 sites in Europe , South America , and Singapore .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Eligible patients were aged 18 years or older , were hospitalised for acute heart failure with concomitant iron deficiency ( defined as ferritin < 100 \u03bcg / L , or 100-299 \u03bcg / L with transferrin saturation < 20 % ) , and had a left ventricular ejection fraction of less than 50 % .", "Evidence Elements": {"Participant": [{"term": "hospitalised", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 65}, {"term": "acute heart failure", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 89}, {"term": "concomitant iron deficiency", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 122}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Before hospital discharge , participants were randomly assigned ( 1:1) to receive intravenous ferric carboxymaltose or placebo for up to 24 weeks , dosed according to the extent of iron deficiency .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "intravenous ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 115}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 126}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "To maintain masking of patients and study personnel , treatments were administered in black syringes by personnel not involved in any study assessments .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was a composite of total hospitalisations for heart failure and cardiovascular death up to 52 weeks after randomisation , analysed in all patients who received at least one dose of study treatment and had at least one post-randomisation data point .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "study treatment", "negation": "affirmed", "UMLS": {}, "start": 201, "end": 216}], "Outcome": [{"term": "composite of total hospitalisations for heart failure and cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 104}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Secondary outcomes were the composite of total cardiovascular hospitalisations and cardiovascular death ; cardiovascular death ; total heart failure hospitalisations ; time to first heart failure hospitalisation or cardiovascular death ; and days lost due to heart failure hospitalisations or cardiovascular death , all evaluated up to 52 weeks after randomisation .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "composite of total cardiovascular hospitalisations and cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 103}, {"term": "cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 103}, {"term": "total heart failure hospitalisations", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 165}, {"term": "time to first heart failure hospitalisation or cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 168, "end": 235}, {"term": "days lost due to heart failure hospitalisations or cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 242, "end": 313}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Safety was assessed in all patients for whom study treatment was started .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "study treatment", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 60}], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "A pre-COVID-19 sensitivity analysis on the primary and secondary outcomes was prespecified .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This study is registered with ClinicalTrials.gov , NCT02937454 , and has now been completed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between March 21 , 2017 , and July 30 , 2019 , 1525 patients were screened , of whom 1132 patients were randomly assigned to study groups .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Study treatment was started in 1110 patients , and 1108 ( 558 in the carboxymaltose group and 550 in the placebo group ) had at least one post-randomisation value .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 83}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 112}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "293 primary events ( 57\u00b72 per 100 patient-years ) occurred in the ferric carboxymaltose group and 372 ( 72\u00b75 per 100 patient-years ) occurred in the placebo group ( rate ratio [ RR ] 0\u00b779 , 95 % CI 0\u00b762-1\u00b701 , p=0\u00b7059 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 87}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 156}], "Outcome": [{"term": "primary events", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 18}, {"term": "rate ratio [", "negation": "affirmed", "UMLS": {}, "start": 165, "end": 177}], "Observation": [], "Count": [{"term": "293", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 3}, {"term": "372", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 101}, {"term": "per", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 29}]}, "Evidence Propositions": [{"Intervention": "placebo", "Observation": "", "Count": "372", "Outcome": "rate ratio ["}]}, {"Section": "FINDINGS", "Text": "370 total cardiovascular hospitalisations and cardiovascular deaths occurred in the ferric carboxymaltose group and 451 occurred in the placebo group ( RR 0\u00b780 , 95 % CI 0\u00b764-1\u00b700 , p=0\u00b7050 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 105}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 143}], "Outcome": [{"term": "total cardiovascular hospitalisations", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 41}, {"term": "cardiovascular deaths", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 67}], "Observation": [], "Count": [{"term": "370", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 3}, {"term": "451", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 119}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "There was no difference in cardiovascular death between the two groups ( 77 [ 14 % ] of 558 in the ferric carboxymaltose group vs 78 [ 14 % ] in the placebo group ; hazard ratio [ HR ] 0\u00b796 , 95% CI 0\u00b770-1\u00b732 , p=0\u00b781 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "two groups", "negation": "negated", "UMLS": {}, "start": 60, "end": 70}, {"term": "ferric carboxymaltose", "negation": "negated", "UMLS": {}, "start": 99, "end": 120}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 149, "end": 156}], "Outcome": [{"term": "cardiovascular death", "negation": "negated", "UMLS": {}, "start": 27, "end": 47}], "Observation": [{"term": "difference", "negation": "negated", "UMLS": {}, "start": 13, "end": 23}], "Count": [{"term": "77 [ 14 % ] of 558", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 91}, {"term": "78 [ 14 % ]", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 141}]}, "Evidence Propositions": [{"Intervention": ["two groups"], "Observation": "difference", "Outcome": "cardiovascular death", "Count": ""}, {"Intervention": "ferric carboxymaltose", "Observation": "", "Count": "77 [ 14 % ] of 558", "Outcome": "cardiovascular death"}, {"Intervention": "placebo", "Observation": "", "Count": "78 [ 14 % ]", "Outcome": "cardiovascular death"}]}, {"Section": "FINDINGS", "Text": "217 total heart failure hospitalisations occurred in the ferric carboxymaltose group and 294 occurred in the placebo group ( RR 0\u00b774 ; 95 % CI 0\u00b758-0\u00b794 , p=0\u00b7013 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 78}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 116}], "Outcome": [{"term": "total heart failure hospitalisations", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 40}], "Observation": [], "Count": [{"term": "217", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 3}, {"term": "294", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 92}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The composite of first heart failure hospitalisation or cardiovascular death occurred in 181 ( 32 % ) patients in the ferric carboxymaltose group and 209 ( 38 % ) in the placebo group ( HR 0\u00b780 , 95 % CI 0\u00b766-0\u00b798 , p=0\u00b7030 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 139}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 170, "end": 177}], "Outcome": [{"term": "composite of first heart failure hospitalisation or cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 76}], "Observation": [], "Count": [{"term": "181 ( 32 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 110}, {"term": "209 ( 38 % )", "negation": "affirmed", "UMLS": {}, "start": 150, "end": 162}]}, "Evidence Propositions": [{"Intervention": "ferric carboxymaltose", "Observation": "", "Count": "181 ( 32 % ) patients", "Outcome": "composite of first heart failure hospitalisation or cardiovascular death"}, {"Intervention": "placebo", "Observation": "", "Count": "209 ( 38 % )", "Outcome": "composite of first heart failure hospitalisation or cardiovascular death"}]}, {"Section": "FINDINGS", "Text": "Fewer days were lost due to heart failure hospitalisations and cardiovascular death for patients assigned to ferric carboxymaltose compared with placebo ( 369 days per 100 patient-years vs 548 days per 100 patient-years ; RR 0\u00b767 , 95 % CI 0\u00b747-0\u00b797 , p=0\u00b7035 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 130}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 152}], "Outcome": [{"term": "days were lost due to heart failure hospitalisations", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 58}, {"term": "cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 83}], "Observation": [{"term": "Fewer", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 5}, {"term": "369 days per 100 patient-years", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 185}, {"term": "548 days per 100 patient-years", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 219}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "Fewer", "Outcome": "", "Count": ""}, {"Intervention": "ferric carboxymaltose", "Observation": "369 days per 100 patient-years", "Outcome": "cardiovascular death", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Serious adverse events occurred in 250 ( 45 % ) of 559 patients in the ferric carboxymaltose group and 282 ( 51 % ) of 551 patients in the placebo group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 92}], "Outcome": [{"term": "Serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 22}], "Observation": [], "Count": [{"term": "250 ( 45 % ) of 559 patients", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 63}, {"term": "282 ( 51 % ) of", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 118}]}, "Evidence Propositions": [{"Intervention": "ferric carboxymaltose", "Observation": "", "Count": "250 ( 45 % ) of 559 patients", "Outcome": "Serious adverse events"}]}, {"Section": "INTERPRETATION", "Text": "In patients with iron deficiency , a left ventricular ejection fraction of less than 50 % , and who were stabilised after an episode of acute heart failure , treatment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations , with no apparent effect on the risk of cardiovascular death .", "Evidence Elements": {"Participant": [{"term": "iron deficiency", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 32}, {"term": "left ventricular ejection fraction of less than 50 %", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 89}, {"term": "acute heart failure", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 155}], "Intervention": [{"term": "ferric carboxymaltose", "negation": "affirmed", "UMLS": {}, "start": 173, "end": 194}], "Outcome": [{"term": "risk of heart failure hospitalisations", "negation": "affirmed", "UMLS": {}, "start": 220, "end": 258}], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 203}, {"term": "reduced", "negation": "affirmed", "UMLS": {}, "start": 208, "end": 215}, {"term": "apparent effect", "negation": "negated", "UMLS": {}, "start": 269, "end": 284}], "Count": []}, "Evidence Propositions": [{"Intervention": "ferric carboxymaltose", "Observation": "reduced", "Outcome": "risk of heart failure hospitalisations", "Count": ""}]}, {"Section": "FUNDING", "Text": "Vifor Pharma .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}